← FDA DRUG APPROVALS

FDA ANDA · ANDA076067

MOMETASONE FUROATE

Sponsor: PADAGIS US

APPLICATION
ANDA076067
TYPE
ANDA
ORIGINAL APPROVAL
2002-03-18
LATEST ACTION
2015-09-23
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Prescription

Products

MOMETASONE FUROATEPrescription
MOMETASONE FUROATE 0.1% · OINTMENT · TOPICAL

Approval history

2015-09-23Labeling · Supplement 9 · standardAP
2007-08-29Labeling · Supplement 5AP
2004-04-05Labeling · Supplement 2AP
2003-01-06Labeling · Supplement 1AP
2002-03-18OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →